Premium
O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing
Author(s) -
Lai Robert,
Albala Bruce,
Kaplow June M.,
Aluri Jagadeesh,
Yen Mark,
Satlin Andrew
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.237
Subject(s) - tolerability , placebo , pharmacokinetics , pharmacodynamics , medicine , dosing , adverse effect , cohort , pharmacology , amyloid beta , gastroenterology , pathology , disease , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom